Japan's Mitsui Acquires Stake In India's Arch Pharma For Direct Presence In The "Global Factory"
This article was originally published in PharmAsia News
Executive Summary
HYDERABAD, India - After Japanese drug giants Daiichi Sankyo, Eisai, Astellas and Takeda, it is the turn of Mitsui - one of the largest and most diverse Japanese industry conglomerates - to evince a direct interest in the Indian pharmaceutical industry
You may also be interested in...
India’s Deal Street Heats Up: Claris, Otsuka, Mitsui In JV To Tap Emerging Markets
The new company will leverage manufacturing and product development competencies to reach out to emerging markets.
Hikma Takes Significant Minority Stake In India's Unimark To Boost Presence Across Global Markets
MUMBAI - Hikma Pharmaceuticals PLC announced it acquired a minority strategic stake in Unimark Remedies Ltd. - a fast-growing Indian intermediates and API manufacturing firm - for $33 million, which could help the Jordanian generics firm expand beyond its Middle East and North Africa (MENA) focus and ramp up capability for the U.S. market
Hikma Takes Significant Minority Stake In India's Unimark To Boost Presence Across Global Markets
MUMBAI - Hikma Pharmaceuticals PLC announced it acquired a minority strategic stake in Unimark Remedies Ltd. - a fast-growing Indian intermediates and API manufacturing firm - for $33 million, which could help the Jordanian generics firm expand beyond its Middle East and North Africa (MENA) focus and ramp up capability for the U.S. market